Lyrica approved for treatment of Fibromyalgia
June 22, 2007
On Thursday, The U.S. Food and Drug Administration approved Pfizer’s Lyrica to treat fibromyalgia, a pain disorder.
The approval marks the first time a drug has been approved for this condition, which is believed to affect three to six million Americans.
Lyrica is already on the market to treat nerve pain associated with diabetes and shingles. The drug had $1.2 billion in sales last year, and has is used by five million people world-wide.
The FDA granted Lyrica priority review status, which cuts four months off the standard 10-month drug review time. Priority Review status is assigned to drug products that, if approved, would be a significant improvement compared to marketed products in the treatment, diagnosis or prevention of a disease.
Comments
Got something to say?
Powered by WordPress
